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AdcAfm Zinc ABC transporter substrate-binding lipoprotein 
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CDAP 1-cyano-4-dimethylaminopyridinium tetrafluoroborate 
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CFU Colony forming units 
CIES Carrier-induced-epitopic suppression 
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DHG Diheteroglycan 
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1. Introductory summary 
1.1 Summary 
Enterococci are natural inhabitants of the gastrointestinal tract and they are the second most common 
Gram-positive pathogens responsible for nosocomial infections. Passive and active immunotherapies 
targeting capsular polysaccharides and surface-associated proteins have emerged as a potential 
prevention and/or treatment strategy against this opportunistically pathogenic bacterium.  
In the first part of this study we evaluated the potential use of two protein immunogens from 
Enterococcus faecium, the secreted antigen A (SagA) and the peptidyl-prolyl cis-trans isomerase (Ppic), 
as carrier proteins conjugated with the capsular polysaccharide diheteroglycan (DHG) from E. faecalis. 
These two glycoconjugates (DHG-SagA and DHG-PpiC) could serve as cross-species vaccines against 
enterococcal infections. For this purpose, rabbits were immunized with the two glycoconjugates, and 
increasing IgG titers against the immunogens and their components were reported. In addition, the 
cross-reactivity of the sera was confirmed by evaluation of their in vitro opsonophagocytic killing activity 
and their immunoreactivity in whole cell ELISA against several E. faecalis and E. faecium strains. The 
sera, also, conferred protection in mice challenged with the respective enterococcal strains. These 
results support the potential use of these proteins as carrier proteins and the ability of these 
glycoconjugate vaccines to provide broader coverage against enterococcal infections. (Publication I) 
In the second part of this study we developed two mAbs against two well characterized immunogens, 
DHG and SagA, from E. faecalis and E. faecium, respectively. For the development of these mAbs mice 
were immunized with the glycoconjugate DHG-SagA, also used in the previous study, and the hybridoma 
technology was used. The implementation of the opsonophagocytic assay for the selection of the 
hybridomas was investigated. The two mAbs developed through this process were further characterized 
for their immunoreactivity by in vitro immunological assays. Both the generated mAbs, DHG.01 and 
SagA.01, exhibited high affinity and specificity to their targets. In addition, the in vitro opsonophagocytic 
killing activity of these mAbs against different enterococcal strains was proven, confirming their cross-
specificity. These mAbs could serve as a potential immunotherapy against enterococcal infections 
especially upon humanization. For this purpose, the sequencing of the mAbs and the evaluation of the 
resulting sequences by the same immunological assays were performed. Finally, the development of 
these two mAbs upon immunization with DHG-SagA, combined with the previous project, confirm that 
SagA is a good carrier protein and that the DHG-SagA glycoconjugate is a potential vaccine candidate 
against prevalent enterococcal species. (Publication II) 
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1.2 Enterococci 
Enterococci are gram-positive, facultative anaerobic oval cocci and lactic acid producers, that form 
chains of various lengths (1). These bacteria exhibit high tolerance to extreme pH conditions, to a wide 
range of temperatures and salt concentrations enabling them to colonize a variety of niches. In addition, 
unlike other bacteria, they are highly tolerant to sodium azide and concentrated bile salts (2). 
Enterococci are commensal bacteria that colonize the gastrointestinal tract of humans even at the early 
life stages (3). Some enterococcal strains have also been used as probiotic agents claiming beneficial 
effects on a number of gastrointestinal and other diseases (4).  
Although they are not a threat for healthy individuals, enterococci are opportunistic pathogens 
associated with hospital-acquired infections making them a serious threat for immunocompromised 
patients. In particular, enterococci can cause serious diseases including endocarditis, bacteremia, and 
meningitis, as well as intra-abdominal, wound, and urinary tract infections (5). The increased prevalence 
of enterococcal infections in humans is mainly attributed to their acquired and intrinsic resistance to 
antibiotics but also to their ability to acquire virulence factors (6). In addition, the biofilm forming 
capacity of enterococci contributes to their persistence during infection and increases their ability to 
endure difficult growth conditions (7).  
The first incidence of endocarditis caused by E. faecalis was reported in 1899, and since then numerous 
studies have tried to shed light on this pathogenic bacterium (8). The first outbreak of enterococcal 
infections was reported in the late 1970s in the United States (US), and currently a new wave, attributed 
to vancomycin-resistant enterococci (VRE), is affecting not only the US but also Europe  (1). In a recent 
study, Cassini et al. reported 16146 cases of VRE infections and 1081 attributable deaths in the European 
Economic Area and European Union in 2015 (9). Southern European countries, e.g. Greece and Portugal, 
have reported the highest rates of VRE associated with nosocomial infections in Europe (10). The two 
most clinically relevant enterococcal species responsible for infections are Enterococcus faecalis and 
Enterococcus faecium, with the highest incidences being initially attributable to  E. faecalis (11). 
However, during the last two decades, E. faecium has become the leading species responsible for 
enterococcal infections both in US and European hospitals, probably due to its high incidence of 
antibiotic resistance compared to E. faecalis (12). In 2017, the World Health Organization published a 
list with 12 antibiotic-resistant pathogens which pose the greatest threat to human health, with E. 
faecium being classified as a high priority for the development of new treatments (13). 
 
1.3 Serotyping of Enterococci  
The initial attempt to establish a system to serotype enterococci was conducted by Sharpe M.E. in 1964 
(14). In 1992, Maekawa et al. were able to distinguish 21 serovars of E. faecalis, and by using sera raised 
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against these serovars they analyzed a collection of 832 E. faecalis strains, from which 77% were typable 
(14). This classification system was based on sera obtained upon immunization of rabbits with formalin-
killed bacteria, providing thus no information regarding defined antigenic structures (e.g. capsules or 
other cell-wall related antigens) (14).  
In 2004, Hufnagel et al. were able to classify 66% of a collection of 29 E. faecalis clinical isolates into 
four capsular polysaccharide serotypes, CPS-A to -D, by immunological selection, using sera raised 
against the capsular polysaccharides of four representative strains, and genetic methods (15). They 
further expanded this study by serotyping 157 clinical and laboratory E. faecalis isolates from four 
different countries, being able to categorize only 42% of the isolates into one of the four serotypes (16). 
Hancock and Gilmore identified a cps locus of 11 open reading frames which was responsible for the 
synthesis of a capsular polysaccharide from E. faecalis Type 2 (17). Although all the serotypes CPS-A to 
-D possess the open reading frames cpsA and cpsB, only the CPS-C and -D serotypes possess the cpsC to 
cpsK, with the cpsF existing only in some CPS-C strains (15). Since seven out of the nine genes of 
the cps locus are important for the production of a capsular polysaccharide, the CPS-A and -B serotypes 
do not express this polysaccharide (18). Theilacker et al. demonstrated that the polysaccharide 
produced by the cps locus is the one that they identified in their study, named diheteroglycan (DHG) 
(19). A few years later, the study of McBride and co-workers demonstrated that half of the CPS-C strains 
examined were more virulent compared to the CPS-A and -B strains, due to the presence of multiple 
virulence and antibiotic resistant traits, as well as to capsular polysaccharides that play critical role in 
the host-pathogen interaction (20).   
 
1.4 Composition of the enterococcal cell wall  
The major cell wall component of Gram-positive bacteria is a peptidoglycan layer, consisting of branches 
of N-acetylmuramic acid-(β1-4)-N-acetylglucosamine (MurNAc-GlcNAc) repeating units, which are 
cross-linked through short peptide bridges (21). The peptidoglycan layer in enterococci is decorated 
with a variety of molecules, which are either covalently linked to the peptidoglycan layer (i.e. 
polysaccharides, teichoic acids, and surface-anchored proteins) or covalently attached to the plasma 
membrane (i.e. lipoteichoic acids and lipoproteins) (Figure 1) (22). 
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Figure 1. Schematic representation of the enterococcal cell wall. Wall teichoic acids, epa (enterococcal 
polysaccharide antigen), surface-anchored proteins and capsule are bound to the muramyl residues of 
the peptidoglycan, whereas lipoproteins and lipoteichoic acid are inserted into the plasma membrane 
(22). 
 
1.4.1 Enterococcal polysaccharides  
In 1999, Wang et al. identified a novel polysaccharide that was present in E. faecalis and a vancomycin 
resistant E. faecium strain. (23). Antisera raised to this polysaccharide were able to mediate opsonic 
killing in vitro and protect against E. faecalis and E. faecium bacteremia (24, 25). The correct structural 
characterization of this polysaccharide, a lipoteichoic acid (LTA), was performed by Theilacker et al., 
revealing a 1,3-polyglycerolphosphate backbone substituted at position C-2 with alanine or 
kojibiose (Figure 2A) (26). While LTA has a glycolipid anchor in the membrane, wall teichoic acids (WTA) 
have a  polyglycerolphosphate or polyribitolphosphate backbone covalently attached to the 
peptidoglycan layer by a phosphodiester bond (27). 
The same polyglycerolphosphate backbone of LTA, is also present in many other clinically important 
Gram-positive pathogens, such as staphylococci, and some streptococci. Theilacker et al. proved that 
antibodies targeting the backbone of LTA are opsonic and protective against E. faecalis and S. 
epidermidis bacteremia, also conferring protection against S. aureus infection (28). In an attempt to 
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develop a vaccine candidate targeting LTA by synthetic approaches, Laverde et al. identified a synthetic 
teichoic acid, WH7, able to absorb out the opsonic activity of antibodies raised against enterococcal LTA 
(Figure 2B). This synthetic oligomer is a promising vaccine candidate against E. faecalis and other Gram-
positive bacteria (29, 30). Another polysaccharide anchored to the peptidoglycan layer is the 
enterococcal polysaccharide antigen (Epa), a rhamnopolysaccharide, and its synthesis is attributed to 
the epa locus (31). This polysaccharide has been suggested to play a role in biofilm formation, resistance 
to neutrophil-mediated phagocytosis, and virulence in a mouse peritonitis model (31–33). 
Although LTA is present in all enterococcal serotypes, it is only surface-exposed in the CPS-A and CPS-B 
serotypes, resulting in the susceptibility of these serotypes to opsonization by the sera raised against 
LTA (34). Serotypes CPS-C and CPS-D possess a capsular polysaccharide, which masks LTA, characterizing 
their surface composition and resulting in a different serological recognition compared to serotypes 
CPS-A and CPS-B (34). This immunogenic capsular polysaccharide DHG was initially identified by Pazur 
et al. (35). The structural elucidation of DHG was accomplished by Theilacker et al. and Krylov et al. 
revealing a repeating unit of →6)-β-Galf-(1→3)-β-D-Glcp-(1→ with O-acetylation in position 5 and lactic 
acid substitution at position 3 of the Galf residue (Figure 2C) (34–36). In the former study, it was also 
shown that rabbit serum raised against DHG mediates opsonophagocytic killing of the encapsulated 
strains in vitro and also reduces the bacterial load in livers and kidneys of mice challenged with these 
strains (34). It was also suggested that passive or active immunotherapy targeting DHG could provide 
protection against enterococcal infections caused by the encapsulated E. faecalis strains (34). 
 
Figure 2. Chemical structure of A. LTA isolated from E. faecalis 12030 (26), B. synthetic teichoic acid 
WH7 (29), and DHG isolated from E. faecalis Type 2 (36). The 1,3-polyglycerolphosphate backbone of 
LTA can be substituted at the position C-2 of the glycerol residues by (R1) d-Alanine, (R2) kojibiose or 
with alanylated kojibiose. 
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1.4.2 Enterococcal proteins 
Bacterial cell-wall-related and secreted proteins play pivotal roles in host-pathogen interactions, 
including adherence, internalization, toxicity, adaptation to environmental changes, and evasion of the 
host defense system (37).  
Three secreted virulence factors have been identified so far in enterococci, named cytolysin (Cyl), 
gelatinase (GelE), and secreted antigen A (SagA) (38). The secreted antigen A (SagA) was initially 
identified in E. faecium by Teng et al., and has been shown to be essential for the bacterial growth as 
well as to bind a number of extracellular matrix proteins, including fibrinogen, collagen type I, collagen 
type IV, fibronectin, and laminin (37). In a recent study, Paganelli et al. identified SagA as the major 
secreted protein during biofilm formation and studied its susceptibility to degradation, its localization 
in the biofilm matrix, and its contribution in biofilm formation of E. faecium (39). Kropec et al. 
demonstrated that immunization with recombinant SagA induces opsonic antibodies against E. faecium 
VRE strains and promotes bacterial clearance in mice challenged with the same bacterial strains. These 
results suggest that active immunotherapy using only SagA or SagA conjugated with polysaccharides 
could serve as a promising vaccine candidate against enterococcal infections (40, 41). Another class of 
virulence factors are the microbial surface components recognizing adhesive matrix molecules 
(MSCRAMMs), such as Ace(42) and Acm (43), and the pilus proteins that promote biofilm formation (44, 
45). 
Although virulence factors are present in many vaccine formulations, any bacterial antigen exposed to 
the immune system can serve as a potential vaccine candidate (46). In this context, Romero-Saavedra 
et al. identified 6 enterococcal proteins that could serve as potential vaccine candidates against 
enterococcal infections by the implementation of transcriptomic (AdcAfm and PsaAfm) and proteomic 
(LysM, DdcP, PpiC, and PBP5) approaches (41, 47). In both studies, rabbits were immunized with the 
recombinant proteins and the resulting sera were evaluated in opsonophagocytic assay (41, 47). The 
sera raised against the proteins were opsonic against the homologous strain (E. faecium E155) but also 
against a collection of E. faecalis and E. faecium strains (41, 47). Moreover, the sera were found to be 
protective in a mouse bacteremia model (41, 47). Both results, indicate the potential use of these 
proteins as vaccine candidates with a broad cross-reactivity and serotype-independent coverage against 
enterococcal infections (41, 47).  
Two of these proteins, AdcAfm and PsaAfm, are a zinc and a manganese ABC transporter substrate-
binding lipoprotein. Lipoproteins are substrate-binding proteins which deliver the substrate to the 
corresponding ABC transporters (48). Interestingly, a homologue of PsaAfm, PsaA, has been studied as 
a promising vaccine candidate with broad coverage against Streptococcus pneumoniae, but also as a 
carrier protein with a synthetic oligosaccharide from S. pneumoniae serotype 14  (49). On the other 
side, a peptidoglycan-binding protein LysM, a D-alanyl-D-alanine carboxypeptidase (DdcP), a peptidyl-
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prolyl cis-trans isomerase (PpiC) and a low affinity penicillin-binding protein 5 (PBP5) are surface-
exposed proteins, which are associated with peptidoglycan (50). Although the function of these proteins 
has not been completely elucidated, these four proteins have been associated with resistance to 
ampicillin and high salt concentrations, and they seem to be involved in bacterial virulence and infection 
(47, 51–54). Finally, apart from targets being localized in the bacterial cell wall, several of these proteins 
were identified in membrane vesicles (MVs) of E. faecium correlating MVs, making enterococcal MVs 
interesting vaccine candidates (50). 
 
1.5 Enterococcal infection and immunity 
Enterococci are natural colonizers of the gastrointestinal tract, usually comprising only a small portion 
of the healthy gut microbiota (55).  Exposure of hospitalized patients to antibiotics against Gram-
negative bacteria distorts the gut microbiota, increasing the prevalence of mostly VRE in the 
gastrointestinal tract (1). Under healthy conditions, lipopolysaccharide and flagellin from Gram-negative 
bacteria induce the production of REGIIIγ. REGIIIγ suppresses the overgrowth of the Gram-positive 
bacteria, including E. faecium. Elimination of the Gram-negative bacteria population decreases REGIIIγ 
leading to the overgrowth of VRE in the gastrointestinal tract (56, 57). Similar shifts in the gut microbiota 
have also been reported in patients undergoing allogeneic hematopoietic stem cell transplantation, 
where the VRE prevalence in the gut was followed by bloodstream enterococcal infections (58). 
The innate immune system constitutes the first line of defense against pathogen invasion. This type of 
defense depends on the recognition of the pathogen-associated molecular patterns (PAMPs), which are 
solely present in the pathogens (59). PAMPs are recognized through pattern recognition receptors, e.g. 
the components of the complement system and the Toll-like receptors (TLRs) (59). There is evidence 
that TLR2 interacts with CD14, playing an important role in the innate immune response against Gram-
positive bacteria by recognizing peptidoglycan and LTA (60). Using an E. faecium peritonitis mouse 
model, Leendertse et al. showed that E. faecium is recognized through TLR2 mediating neutrophil influx 
to the site of infection and bacterial clearance (61). In the same model it was also found that peritoneal 
macrophages (62), neutrophils (61) and the complement system (63) are essential for the rapid 
eradication of this bacterium in the early stages of the infection. 
Apart from the direct interaction of the pathogen with the phagocyte through the PAMPs-TLR 
interaction, there is also an indirect pathway mediated through a class of molecules called opsonins, 
comprised of immunoglobulins and complement components (64). Activation of the alternative 
complement pathway elicits deposition of the complement component C3b on the bacterial surface, 
which is subsequently recognized by complement receptors on the phagocytes (65). On the other side, 
IgGs  trigger the FcγRs and activate the classical complement pathway resulting in the uptake of the 
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bacteria by the neutrophils (65). In encapsulated Gram-positive bacteria, like enterococci, the 
combination of these two mechanisms is crucial for efficient phagocytosis of the bacteria (65–67). 
Immediately upon formation of the phagosome its maturation starts, and the phagosome subsequently 
is fused with the lysosome for the formation of the phagolysosome, which is a microbicidal organelle 
(64).  
In a study of Arduino et al. it was found that 50% of the E. faecium strains tested were resistant to 
phagocytosis, evading internalization by PMNs, which may be attributable to carbohydrate structures 
in their cell surface (68). In addition, there have also been reported cases where enterococci were able 
to resist killing despite their internalization by the phagocytes (69–71). The incompetence of the 
immune system to kill the intracellular enterococci may lead to their systemic spread (5). 
 
1.6 Antibiotic resistance and options for treatment 
Enterococci not only possess intrinsic resistance to several antibiotics, but also may develop acquired 
resistance through sporadic mutations or by the acquisition of exogenous resistance genes (i.e. by 
pheromone-sensitive plasmids, broad host range plasmids, or through transposon movement) (6). 
Approximately 90% of the clinical isolates from E. faecium are ampicillin resistant (1). In most cases 
resistance to β-lactam antibiotics in enterococci is attributed to the expression of low affinity penicillin 
binding proteins (PBPs) (72). Since enterococci are intrinsically resistant to aminoglycosides (e.g. 
gentamycin and streptomycin) due to their low bacterial uptake, in vitro studies have supported the 
synergistic effect of penicillin co-administration (1, 73). Still there are instances where this scheme is 
inadequate, especially when high-level resistance to aminoglycosides is encountered (74). 
The first VRE strain was isolated in 1986 (75). Vancomycin belongs to the glycopeptides, a class of 
antibiotics that inhibits the peptidoglycan synthesis (76). VRE modify the D-alanyl-D-alanine terminus of 
the N-acetylmuramic acid and N-acetylglucosamine peptides to D-Ala-D-lactate or D-Ala-D-serine, 
reducing the affinity of the glycopeptides to the peptides but not affecting the biosynthesis of the cell 
wall (76). The van gene clusters are responsible for this type of resistance, with VanA and VanB being 
the most prevalent in Europe, providing a series of enzymes that facilitate the signal transduction, the 
synthesis of the D-lactate and D-serine, and their subsequent ligation to the precursor molecules, as 
well the elimination of the alternative biosynthetic pathway (10, 76). Each of these clusters provides 
different susceptibility levels to the enterococcal species, for instance the VanA cluster provides high-
level resistance to vancomycin and teicoplanin, whereas strains possessing the VanB cluster retain their 
susceptibility to teicoplanin (77). 
Alternative antibiotic agents, such as quinupristin-dalfopristin, daptomycin, tigecycline, and linezolid, 
have entered the clinical practice to fight VRE infections. However, resistance to these agents has 
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already been reported (10). Resistance to streptogramins and quinupristin/dalfopristin includes 
enzymatic acetylation of the drugs (78, 79), methylation of the 23S rRNA (80), and efflux pumps (80, 
81). Clinical data suggest that quinupristin/dalfopristin could be beneficial in the treatment of E. faecium 
endocarditis especially as part of a combination therapy (82, 83). The two cell membrane proteins GdpD 
and LiaF are associated with resistance to daptomycin (84). Daptomycin is approved for skin and soft 
tissue VRE infections, and its efficacy against infective endocarditis, either as a monotherapy or in 
combination with aminoglycosides, ampicillin, or tigecycline, should be further investigated (85, 86). 
Resistance to linezolid has been attributed to mutations in the domain V of the 23S rRNA or alterations 
in the methylation of the 23S rRNA (87, 88). Generally, it is recommended linezolid as an alternative 
treatment for VRE endocarditis when other therapeutic options are not available (85, 86). 
 
1.7 Alternative treatment methods against Enterococci 
A current challenge in the treatment of enterococcal infections in the clinical setting is their resistances 
to most conventional antibiotics (89). This underscores the necessity for the development of new types 
of treatment or prevention, such as passive or active immunotherapies. As mentioned above, capsular 
and cells wall polysaccharides, but also cell-surface associated protein antigens can serve as targets for 
the development of immunotherapies. 
An enterococcal vaccine could be beneficial in high risk patients for enterococcal infection, reducing the 
mortality rates and the hospital stay of this population (90). For this purpose studies that establish risk 
factors in well-defined patient populations are of major importance (91, 92). All the polysaccharides 
mentioned above could serve as good antigens in vaccine formulations against enterococcus. However, 
polysaccharides are poorly immunogenic, triggering T cell-independent immune response and in most 
cases are unable to elicit memory B cells (93). Chemical conjugation of polysaccharides with a carrier 
protein can overcome these obstacles. In particular, the carrier protein directs the processing of the 
glycoconjugate by polysaccharide-specific B cells. As a consequence the processed antigen is presented 
through the MHC class II molecule to the carrier-peptide-specific T cells, provoking thus, T cell-
dependent immune responses, affinity maturation and B cell memory (Figure 3) (93). Currently, several 
licensed glycoconjugate vaccines have been proven to be safe and successful in the prevention of 
infectious diseases against Haemophilus influenza, meningococcus serogroups A, C, and ACWY, 10 to 13 
serotypes of pneumococcus, and Salmonella typhi (94). Apart from their implementations in the vaccine 
industry, glycoconjugates have also served as immunogens for the production of polysaccharide specific 
mAbs in mice (95–97).  
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Figure 3. Immune response to polysaccharide and glycoconjugate vaccines. A. Immunization with 
polysaccharides stimulates B cells, and promotes the production of antibodies, without eliciting B cell 
memory. B. Glycoconjugate vaccines are processed by polysaccharide-specific B cells, and the resulting 
peptides are presented to carrier-peptide-specific T cells, inducing T cell help for the production of 
memory B cells and plasma cells. CD40L, CD40 ligand; TCR, T-cell receptor; B-cell receptor; modified 
from (93). 
 
As it was discussed above, carrier proteins in glycoconjugate vaccines facilitate the T cell-dependent 
immune response to the conjugated polysaccharide, which is a T cell-independent antigen. The 
currently licensed carrier proteins for glycoconjugated vaccines are diphtheria toxoid, tetanus toxoid, 
CRM197, Haemophilus protein D, and the outer membrane protein complex of serogroup B 
meningococcus (98). In an attempt to simplify vaccine formulations, to broaden the vaccine coverage, 
and to overcome carrier-induced-epitopic suppression (CIES), there is an emerging interest in the 
identification of new carrier proteins (98, 99).  In this context, conjugates of polysaccharide and protein 
virulence factors from the same bacterium, where proteins play a dual role not only as a carrier protein 
but also as an immunogen, have been proposed (98).  
Passive immunotherapy using mAbs is an emerging field with many promising candidates to fight these 
health threats (100). Despite their short-lasting effect, mAbs possess several advantages over vaccines. 
In particular, they can have a faster effect, with lower number of doses, could be easily produced at 
industrial level, and most importantly even immunosuppressed individuals can profit from this type of 
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treatment (101). Up to date a limited number of mAbs against enterococci exists in the literature. In a 
recent study from Rossmann et al., two opsonic mAbs targeting enterococci were developed, exhibiting 
promising results in vivo and in vitro (102). In this study, it was also proposed that these mAbs are 
directed against LTA, providing a limited coverage to the E. faecalis serotypes, since anti-LTA antibodies 
fail to opsonize the CPS-C and -D E. faecalis serotypes (34, 102). Two other mAbs targeting the 
enterococcal proteins Adhesin to collagen (Ace) and the major component of pili (EbpC) are also in 
preclinical phase  (103, 104). The effectiveness of these mAbs against non-encapsulated E. faecalis 
strains provides further support for the development of mAbs against enterococcal infections. In 
addition, further research has to be performed in the selection of the immunogenic targets for the 
development of mAbs since the major barrier of mAb development is the antigenic heterogeneity of 
clinically relevant pathogens (105). The potential of this type of treatment has also been proven by the 
evaluation of human hyperimmune globulin preparations, which contain opsonic and protective 
antibodies against multidrug resistant Gram-positive and -negative bacteria (106). 
 
1.8 Aim of the thesis 
The intrinsic and acquired resistance of enterococcal species to most commonly used antibiotics has 
contributed to a high frequency of isolates in European and US hospitals. The overall aim of this PhD 
was to develop alternative treatments against multidrug resistant enterococci. For this purpose, active 
(Publication I) and passive (Publication II) immunotherapy regiments were developed.  
In the first publication, we evaluated the potential use of two enterococcal proteins, SagA and Ppic, as 
antigens and carriers for enterococcal carbohydrate immunogens in order to develop cross-species 
vaccines against enterococci. As it has been discussed above, both of these antigens have been proven 
to be good immunogens for the development of vaccines against enterococci (Section: Enterococcal 
proteins). The increasing demand for multivalent vaccines and vaccine co-administration can reduce the 
efficacy of the glycoconjugate vaccines by affecting the immune response, e.g. by CIES or bystander 
interferences (107). This obstacle can be overcome by the use of alternative carrier proteins that could 
furthermore contribute in the development of vaccines targeting several virulence factors of pathogens 
(107). The incorporation of multiple bacterial components, e.g. toxoids, capsular polysaccharides, and 
cell-wall associated proteins, could contribute in the development of an effective vaccine (108). 
Addressing this issue in the first publication we semi-synthesized the glycoconjugates of SagA and PpiC 
with the enterococcal capsular polysaccharide DHG and we evaluated them in rabbits. Since a protective 
immune response against enterococci is mediated through PMNs and requires both antibodies and 
complement, the opsonophagocytic assay is a reliable in vitro method to be used as a surrogate of 
protective immune response in order to evaluate the efficacy of enterococcal vaccines (25, 47, 109). 
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For this purpose, the sera raised in rabbits upon immunization with the two glycoconjugates were 
evaluated by opsonophagocytic assay against several enterococcal strains. In addition, the cross-
reactivity of the sera was evaluated in whole cell ELISA for enterococcal strains that could not be 
evaluated in the opsonophagocytic assay. Animal studies were performed to assess whether the elicited 
antibodies were able to confer protection in mice challenged with the respective bacteria. These results 
confirmed that the antigens DHG-PpiC and DHG-SagA were able to elicit opsonic and protective 
antibodies targeting both their components. Moreover, the glycoconjugates from this project could not 
only serve as vaccine candidates, but could also be used in the second part of this PhD as immunogens 
for the production of antigen specific mAbs in mice (95–97).  
The aim of the second part of this PhD was to identify and develop opsonic and protective mAbs that 
target two well-characterized antigens, DHG and SagA, from E. faecalis and E. faecium, respectively. 
These mAbs could be used as a prophylactic therapy against enterococci either as monotherapy or as a 
supplementary therapy with antibiotics having a synergistic effect on the eradication of enterococcal 
infections. The antigenic heterogeneity of pathogens isolated from patients limits the successful 
application of therapeutic mAbs (105). This antigenic variation in clinical pathogens necessitates either 
cross-reacting mAbs, cocktails of mAbs, or rapid accurate diagnosis prior to administration (105). 
Despite the fact that the high specificity of the mAbs may limit the coverage that they provide compared 
to polyclonal sera, mAbs can provide many advantages since they are well-defined reagents with high 
consistency in production (110). Enterococci have been classified to a limited number of serotypes 
(Section: Serotyping of enterococci) (90). Taking this into consideration, these two newly developed 
mAbs targeting the CPS-C and -D serotypes of E. faecalis (mAb against DHG) and E. faecium (mAb against 
SagA) combined with the previously developed mAb targeting the CPS-A and -B serotypes (mAb against 
LTA) (102), could provide an extended coverage to enterococcal strains. Other monoclonal antibodies 
against enterococci in the literature have been tested only against one (103, 104) maximum two 
enterococcal strains (102), and despite the great importance of these studies, this issue is substantially 
critical and is addressed in our study. For this project we decided to use hybridoma technology, which 
is a well-established technique for the generation of mAbs targeting polysaccharide and protein 
antigens against bacterial pathogens (95, 96, 111–113). For this purpose, mice were immunized with 
the glycoconjugate DHG-SagA, which was reported in the previous study, in order to elicit opsonic and 
protective antibodies against both antigens. The opsonophagocytic activity of the mAbs was validated. 
This test is a good indicator of the mAb activity, since it has been observed that in vitro 
opsonophagocytic activity of mAbs is usually correlated with a protective immune response against 
bacterial pathogens in vivo (114). The affinity and specificity of the two mAbs was evaluated by in vitro 
immunological assays and kinetic studies. Future studies should validate the in vivo protective efficacy 
of these mAbs and attempt to humanize them in order to increase their therapeutic potential. In an 
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effort to pursue this latter goal we performed sequencing of the variable regions of the mAbs and we 
validated the synthetic constructs of the heavy and light chain with ELISA and opsonophagocytic assay. 
Moreover, the elucidation of the protective epitope and the minimal binding requirements of the anti-
polysaccharide mAb could contribute to the rational design of structurally defined vaccines that are 
easily manufactured through synthetic approaches (115). Furthermore, the anti-protein mAb could be 
used in the epitope mapping of the protein for elucidation of the immunogenic epitopes that should be 
preserved upon conjugation (98). 
Finally, both studies describe the feasible development of therapeutic tools that could be implemented 
in the eradication of enterococcal infections in the clinical setting. In addition, both studies pursue to 
combat the antigenic variability of the pathogen by targeting multiple antigens, which according to 
serotyping, the elucidation of the carbohydrate composition of enterococci, and to our current 
knowledge regarding enterococcal antigens, could provide a broad protection against these pathogenic 
strains. Studies in serotyping as well as the examination of a bigger collection of clinically isolated 
enterococcal strains would provide further insights in the therapeutic potential of these two strategies. 
 
1.9 Contribution to publications  
In the first article the main research work was conducted by Dr Diana Laverde and Dr Felipe Romero-
Saavedra (first co-authors). I participated in the immunogen preparation (protein purification), the 
preparation of the sera (sera purification), in the analysis of the results and in the writing of this 
manuscript by reviewing, correcting and editing the manuscript in all the submissions as well as in all 
the revision steps. The analysis of the results of this work lead to the use of the same glycoconjugate, 
DHG-SagA, for the development of the mAbs of the second project. The second article was the main 
focus of my work and thus lead to my first-author publication. I started this project under the supervision 
of Prof Dr med Johannes Hübner and Dr Diana Laverde, and I was responsible for the planning, 
management and implementation of this project. I participated in all the experiments described and in 
their analysis. The hybridomas were developed during my secondment in the Center of Proteomics, 
Rijeka, Croatia, under the guidance and assistance of Karmela Miklic and Prof Dr Tihana Lenac Rovis, 
and the SPR experiments were performed during my secondment in GSK, Siena, Italy, under the 
guidance of Dr Filippo Carboni and Dr Roberto Adamo. I performed the ELISAs, Western blots and the 
majority of the opsonophagocytic assays presented in the figures. In addition, I performed the 
sequencing of the mAbs and I reconstructed them under the guidance of Dr Felipe Romero-Saavedra, 
and I performed the expression of the recombinant mAbs in the eykaryotic cells and their final 
evaluation by ELISA and opsonophagocytic assays. Finally, I performed the analysis of all these data as 
well as writing and submitting the final manuscript presented in this PhD.  
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